About Alnylam
Alnylam is a company based in Cambridge (United States) founded in 2002 by Paul Schimmel, Phillip Sharp, and John Clarke. Alnylam has raised $17 million across 7 funding rounds from investors including Blackstone, Arch Venture Partners and Atlas Venture. The company has 2,230 employees as of December 31, 2024. Alnylam has completed 2 acquisitions, including Nucleonics and Sirna Therapeutics. Alnylam operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, ATAI, Insitro and Ultragenyx, among others.
- Headquarter Cambridge, United States
- Employees 2230 as on 31 Dec, 2024
- Founders Paul Schimmel, Phillip Sharp, John Clarke
- Stage Public
-
Sectors
HealthcareTechnology
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Alnylam Pharmaceuticals, Inc.
-
Annual Revenue
$2.25 B (USD)22.97as on Dec 31, 2024
-
Net Profit
-$278.16 M (USD)36.82as on Dec 31, 2024
-
EBITDA
-$120.22 M (USD)47.3as on Dec 31, 2024
-
Total Equity Funding
$17 M (USD)
in 7 rounds
-
Latest Funding Round
$150 M (USD), Post-IPO
Aug 17, 2020
-
Investors
Blackstone
& 7 more
-
Employee Count
2230
as on Dec 31, 2024
-
Investments & Acquisitions
Nucleonics
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Alnylam
Alnylam is a publicly listed company on the NASDAQ with ticker symbol ALNY in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Alnylam
Unlock access to complete
Unlock access to complete
Software Development Team
142 people
Leadership Team
113 people
Senior Team
52 people
Finance and Accounting
36 people
Operations Team
31 people
Legal and Compliance
30 people
Human Resources and Administration
28 people
Principal Team
27 people
Unlock access to complete
Funding Insights of Alnylam
Alnylam has successfully raised a total of $17M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $150 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Alnylam
Alnylam has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Blackstone, Arch Venture Partners and Atlas Venture.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified investment management is provided across multiple asset classes.
|
Locked | Locked | Locked | |
|
Early stage venture capital firm investing in US
|
Locked | Locked | Locked | |
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked |
Investor details for Alnylam
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alnylam
Alnylam has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Nucleonics and Sirna Therapeutics.
Investment portfolio details for Alnylam
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
RNAi therapeutics for viral diseases including Hepatitis-B were developed.
|
Locked | Locked | 2001 | Locked | |
|
Develops RNAi-based therapies
|
Locked | Locked | 1992 | Locked |
Complete acquisition details for Alnylam
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Alnylam
Detailed financials for Alnylam
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alnylam Comparisons
Peer comparison for Alnylam
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alnylam
Alnylam operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, ATAI, Insitro and Ultragenyx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of Alnylam
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alnylam
Complete news archive for Alnylam
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alnylam
Alnylam was founded in 2002.
Alnylam is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
John Maraganore is the current CEO of Alnylam.
Alnylam is a funded company, having raised a total of $17M across 7 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Alnylam is 2,230.
Annual revenue of Alnylam is $2.25B as on Dec 31, 2024.
Alnylam was founded in 2002 and is headquartered in Cambridge, United States. RNA interference therapeutics are developed for genetic and other disorders within the biotechnology sector. The pipeline encompasses treatments for hereditary ATTR amyloidosis, acute hepatic porphyria, and hypercholesterolemia. Further development targets cardiometabolic conditions, infectious diseases, central nervous system disorders, and ocular diseases. Operations emphasize research and drug advancement in these areas.
Alnylam's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Yes, Alnylam is publicly traded on NASDAQ under the ticker symbol ALNY.
Alnylam has made 2 acquisitions, including Nucleonics, and Sirna Therapeutics.
Alnylam has 8 investors. Key investors include Blackstone, Arch Venture Partners, Atlas Venture, Genzyme, and Abingworth.
The ticker symbol of Alnylam is ALNY on NASDAQ.